Recombinant human interleukin-7 for patients with infection-associated lymphopenia: a systematic review and meta-analysis [0.03%]
Xin Lu,Yuejuan Shi,Linlin Chen et al.
Xin Lu et al.
Purpose: This study aims to evaluate the efficacy of recombinant human interleukin-7 (rhIL-7) in treating lymphopenia and related clinical outcomes in patients with infection-associated lymphopenia through a meta-analysis...
Lieven Dupont,Charles Pilette,Maud Deschampheleire et al.
Lieven Dupont et al.
Background: Benralizumab is an anti-IL-5Rα antibody used as add-on maintenance therapy in patients with severe eosinophilic asthma (SEA). Materials and m...
H Salawati,Yaoqin Lu,Feifei Li et al.
H Salawati et al.
Background: China faces a severe tuberculosis (TB) situation, particularly in Xinjiang. This study analyzed the influence of age, period, and birth cohort on TB incidence trends in the region. ...
Medication adherence to cystic fibrosis transmembrane conductance regulator (CFTR) modulators: Analysis on the French cystic fibrosis population from 2012-2020 [0.03%]
Elia Eid,Cécile Payet,Violaine Fernandez et al.
Elia Eid et al.
Background: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators, ivacaftor and lumacaftor/ivacaftor, were introduced in France in 2012 and 2015, respectively, and transformed treatment landscape. Real-wo...
Dupilumab-induced eosinophilia in severe asthma: 2-year follow-up real-life evidence from biologic-naïve and previously treated patients [0.03%]
Cristina Bellver-Asperilla,Ana Romero Ortíz,Héctor Cabrerizo-Carreño et al.
Cristina Bellver-Asperilla et al.
Data from real-life settings regarding dupilumab-associated eosinophilia remains limited, particularly concerning potential risk factors for developing hypereosinophilia after treatment initiation. ...
Patient's perspectives about the immediate online access of bronchoscopy biopsy results through a patient portal [0.03%]
Sallam Alrosan,Motaz Daraghma,Matthew Aboudara
Sallam Alrosan
Background: The 21st Century Cures Act Final Rule requires healthcare organizations to immediately release patient results through an online portal. This may improve patient safety and reduce anxiety. However, little is k...
Impact of pre-existing interstitial lung abnormalities on pneumonitis risk and survival in chemo-naive patients with non-small-cell lung cancer receiving pembrolizumab plus chemotherapy [0.03%]
Hirotomo Machiyama,Kinnosuke Matsumoto,Takayuki Shiroyama et al.
Hirotomo Machiyama et al.
Background: Pre-existing interstitial lung abnormalities (ILAs) are risk factors for immune checkpoint inhibitor related pneumonitis (ICI-P). However, the effects of first-line pembrolizumab plus platinum-based chemothera...
Mikołaj Najda,Yuyang Yan,Loes van Bemmel et al.
Mikołaj Najda et al.
Background: COPD and asthma cause significant morbidity and mortality across the globe. The development of non-invasive telemonitoring solutions offers the potential to improve patient care. ...
Temporal trends in baseline severity and 12-month response to mepolizumab in severe asthma: The TYREX multicentre real-world study in Spain (2017-2024) [0.03%]
Javier Domínguez-Ortega,Carlos Almonacid,Francisco Javier Alvarez-Gutiérrez et al.
Javier Domínguez-Ortega et al.
Background and objective: Although mepolizumab has demonstrated efficacy and effectiveness in the treatment of severe asthma, it is unknown whether the characteristics of patients starting this biologic have changed over ...
High COPD Prevalence Among Socially Marginalized Hospitalized Patients. A Pragmatic Multicenter Prospective Cohort Study [0.03%]
Nina Brünés,Mette Bendtz Lindstroem,Thomas Kallemose et al.
Nina Brünés et al.
Background: Tobacco exposure is the main risk factor for chronic obstructive pulmonary disease (COPD), but other risk factors, including low socio-economic status (SES), may also contribute. Danish hospitals have introduc...